Overview

Europe In-Vitro Diagnostics Market is estimated to register a CAGR of over 5.5% during the forecast period 2020 to 2027.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Europe In-Vitro Diagnostics Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Europe In-Vitro Diagnostics Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Europe In-Vitro Diagnostics Market:
•  Abbott Laboratories
•  Becton, Dickinson and Company
•  Bio-Rad Laboratories Inc.
•  Danaher Corporation (Beckman Coulter, Inc)
•  Johnson & Johnson
•  Roche Diagnostics
•  Siemens Healthcare
•  Thermo Fisher Scientific Inc.
•  Sysmex Corporation
•  QIAGEN
•  BioMerieux SA
•  Tesa SE
•  Cepheid, Inc.
•  Hologic, Inc. (Gen Probe)
•  OraSure Technologies
•  Alere, Inc.
•  Quidel Corporation
 (Note: The list of the major players will be updated with the latest market scenario and trends)

Europe In-Vitro Diagnostics Market Segmentation:
 

By Test Type
• Clinical Chemistry
• Molecular Diagnostics
• Hematology
• Immuno Diagnostics
• Other Test Types

By Product
• Instrument
• Reagents
• Other Products

By Usability
• Disposable IVD Devices
• Reusable IVD Devices

By Application
• Infectious Disease
• Diabetes
• Cancer/Oncology
• Cardiology
• Autoimmune Disease
• Nephrology
• Other Applications

By End User
• Diagnostic Laboratories
• Hospitals and Clinics
• Other End Users

By Region
• Germany
• U.K        
• Italy
• Spain
• Russia
• Poland
• Rest of Europe

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Europe In-Vitro Diagnostics Market By Test Type, By Product, By Usability, By Application, By End User and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— Germany, U.K, Italy, Spain, Russia, Poland, Rest of Europe
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
  1.1 Objectives of the Study
  1.2 Market Definition
  1.3 Market Scope
      1.3.1 Years Considered for the Study
      1.3.2 Market Covered
  1.4 Currency
  1.5 Limitations
  1.6 Stakeholders

2. Research Methodology
   2.1 Research Data
       2.1.1 Secondary Data
             2.1.1.1 Key Data from Secondary Sources
       2.1.2 Primary Data
             2.1.2.1 Key Data from Primary Sources
   2.2 Market Size Estimation
   2.3 Market Breakdown and Data Triangulation
   2.4 Assumptions for the Study  

3. Executive Summary
  3.1 Market Outlook
  3.2 Segment Outlook
  3.3 Competitive Insights

4. Europe In-Vitro Diagnostics Market Variables, Trends & Scope
  4.1. Market Lineage Outlook
  4.2. Penetration and Growth Prospect Mapping
  4.3. Industry Value Chain Analysis
  4.4. Cost Analysis Breakdown
  4.5. Technology Overview
  4.6. Regulatory Framework
       4.6.1. Reimbursement Framework
       4.6.2. Standards and Compliances

5. Market Overview
  5.1. Market Dynamics
       5.1.1. Market Driver Analysis
              5.1.1.1. Increasing focus of Europe In-Vitro Diagnostics Companies on Brand Protection
              5.1.1.2. Untapped Opportunities in Emerging Regions
       5.1.2. Market Restraint Analysis
              5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
       5.1.3. Industry Challenges
              5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Europe In-Vitro Diagnostics Market Analysis Tools
  6.1. Industry Analysis - Porter’s
       6.1.1. Supplier Power
       6.1.2. Buyer Power
       6.1.3. Substitution Threat
       6.1.4. Threat from New Entrants
       6.1.5. Competitive Rivalry
  6.2. Pestel Analysis
       6.2.1. Political Landscape
       6.2.2. Environmental Landscape
       6.2.3. Social Landscape
       6.2.4. Technology Landscape
       6.2.5. Legal Landscape
  6.3. Major Deals And Strategic Alliances Analysis
       6.3.1. Joint Ventures
       6.3.2. Mergers and Acquisitions
       6.3.3. Licensing and Partnership
       6.3.4. Technology Collaborations
       6.3.5. Strategic Divestments
  6.4. Market Entry Strategies
  6.5. Case Studies

7. Europe In-Vitro Diagnostics Market, By Test Type Historical Analysis and Forecast 2020-2027 (USD Million)
  7.1. Clinical Chemistry
  7.2. Molecular Diagnostics
  7.3. Hematology
  7.4. Immuno Diagnostics
  7.5. Other Test Types

8. Europe In-Vitro Diagnostics Market, By Product Historical Analysis and Forecast 2020-2027 (USD Million)
  8.1. Instrument
  8.2. Reagents
  8.3. Other Products

9. Europe In-Vitro Diagnostics Market, by Usability Historical Analysis and Forecast 2020-2027 (USD Million)
  9.1. Disposable IVD Devices
  9.2. Reusable IVD Devices

10. Europe In-Vitro Diagnostics Market, by Application Historical Analysis and Forecast 2020-2027 (USD Million)
  10.1. Infectious Disease
  10.2. Diabetes
  10.3. Cancer/Oncology
  10.4. Cardiology
  10.5. Autoimmune Disease
  10.6. Nephrology
  10.7. Other Applications

11. Europe In-Vitro Diagnostics Market, by End User Historical Analysis and Forecast 2020-2027 (USD Million)
  11.1. Diagnostic Laboratories
  11.2. Hospitals and Clinics
  11.3. Other End Users

12. Europe Europe In-Vitro Diagnostics Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   12.1. Introduction
   12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         12.2.1. Germany
         12.2.2. U.K        
         12.2.3. France
         12.2.4. Italy
         12.2.5. Spain
         12.2.6. Russia
         12.2.7. Poland
         12.2.8. Rest of Europe
   12.3. Market Size (USD Million) Forecast for Europe 2020-2027

13. Market Share Analysis and Competitive Landscape  
   13.1. Europe Landscape - Key Players, Revenue and Presence
   13.2. Europe Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
   13.3. Europe Emerging Companies
   13.4. Europe - Market Share Analysis and Key Regional Players
   13.5. Europe Key Player - Growth Matrix

14. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
   14.1. Abbott Laboratories
         14.1.1. Company Overview
         14.1.2. Product Portfolio
         14.1.3. SWOT Analysis
         14.1.4. Financial Overview
         14.1.5. Strategic Overview
   14.2. Becton, Dickinson and Company
         14.2.1. Company Overview
         14.2.2. Product Portfolio
         14.2.3. SWOT Analysis
         14.2.4. Financial Overview
         14.2.5. Strategic Overview
   14.3. Bio-Rad Laboratories Inc.
         14.3.1. Company Overview
         14.3.2. Product Portfolio
         14.3.3. SWOT Analysis
         14.3.4. Financial Overview
         14.3.5. Strategic Overview
   14.4. Danaher Corporation (Beckman Coulter, Inc)
         14.4.1. Company Overview
         14.4.2. Product Portfolio
         14.4.3. SWOT Analysis
         14.4.4. Financial Overview
         14.4.5. Strategic Overview
   14.5. Johnson & Johnson
         14.5.1. Company Overview
         14.5.2. Product Portfolio
         14.5.3. SWOT Analysis
         14.5.4. Financial Overview
         14.5.5. Strategic Overview          
   14.6. Roche Diagnostics
         14.6.1. Company Overview
         14.6.2. Product Portfolio
         14.6.3. SWOT Analysis
         14.6.4. Financial Overview
         14.6.5. Strategic Overview      
   14.7. Siemens Healthcare
         14.7.1. Company Overview
         14.7.2. Product Portfolio
         14.7.3. SWOT Analysis
         14.7.4. Financial Overview
         14.7.5. Strategic Overview
   14.8. Thermo Fisher Scientific Inc.
         14.8.1. Company Overview
         14.8.2. Product Portfolio
         14.8.3. SWOT Analysis
         14.8.4. Financial Overview
         14.8.5. Strategic Overview
   14.9. Sysmex Corporation
         14.9.1. Company Overview
         14.9.2. Product Portfolio
         14.9.3. SWOT Analysis
         14.9.4. Financial Overview
         14.9.5. Strategic Overview
   14.10.QIAGEN
         14.10.1. Company Overview
         14.10.2. Product Portfolio
         14.10.3. SWOT Analysis
         14.10.4. Financial Overview
         14.10.5. Strategic Overview
   14.11.BioMerieux SA
         14.11.1. Company Overview
         14.11.2. Product Portfolio
         14.11.3. SWOT Analysis
         14.11.4. Financial Overview
         14.11.5. Strategic Overview
   14.12.Tesa SE
         14.12.1. Company Overview
         14.12.2. Product Portfolio
         14.12.3. SWOT Analysis
         14.12.4. Financial Overview
         14.12.5. Strategic Overview
   14.13.Cepheid, Inc.
         14.13.1. Company Overview
         14.13.2. Product Portfolio
         14.13.3. SWOT Analysis
         14.13.4. Financial Overview
         14.13.5. Strategic Overview
   14.14.Hologic, Inc. (Gen Probe)
         14.14.1. Company Overview
         14.14.2. Product Portfolio
         14.14.3. SWOT Analysis
         14.14.4. Financial Overview
         14.14.5. Strategic Overview
   14.15. OraSure Technologies
         14.15.1. Company Overview
         14.15.2. Product Portfolio
         14.15.3. SWOT Analysis
         14.15.4. Financial Overview
         14.15.5. Strategic Overview          
   14.16.Alere, Inc.
         14.16.1. Company Overview
         14.16.2. Product Portfolio
         14.16.3. SWOT Analysis
         14.16.4. Financial Overview
         14.16.5. Strategic Overview      
   14.17.Quidel Corporation
         14.17.1. Company Overview
         14.17.2. Product Portfolio
         14.17.3. SWOT Analysis
         14.17.4. Financial Overview
         14.17.5. Strategic Overview      

15. Pre and Post COVID-159 Impact
   15.1. Positive influence on the healthcare industry
   15.2. The financial disruption of the manufacturing sector
   15.3. Impact of COVID-19 on emerging companies
   15.4. Significant mandates in the healthcare regulations initiated by administrations
   15.5. The overall economic slowdown of the developing and developed nations

16. FutureWise SME Key Takeaway Points for Client

Tables

Figures